<?xml version="1.0" encoding="UTF-8"?>
<p>Adult patients with NDMM (transplant eligible or ineligible) and measurable disease (defined as: serum M‐protein ≥10 g/l, urine M‐protein ≥200 mg/24 h, or involved free light chain (FLC) ≥100 mg/l if the serum FLC ratio was abnormal), Eastern Cooperative Oncology Group (ECOG) performance status 0–2, and adequate renal, hepatic, cardiac and haematological function were eligible. Patients were excluded if they had: grade ≥2 peripheral neuropathies not elsewhere classified (NEC; high‐level term including peripheral neuropathy [PN] and peripheral sensory neuropathy); major surgery or an infection necessitating antibiotics within 14 days of commencing study treatment; prior treatment for MM; uncontrolled cardiovascular disorders within the past 6 months; previous deep‐vein thrombosis (DVT); prolonged QT interval; or known human immunodeficiency virus/hepatitis infection. For detailed eligibility criteria see Table 
 <xref rid="bjh15394-sup-0001" ref-type="supplementary-material">SI</xref>. All patients provided written, informed consent at the time of enrolment.
</p>
